the EAHAD Podcast

Welcome to the second module of the EAHAD E-Learning Working Group podcast, where we are excited to feature Carmen Escuriola-Ettingshausen as our guest speaker. In this episode, Carmen will be discussing the topic of "ITI in the era of emicizumab." Emicizumab, a new therapeutic option for people with hemophilia A, has introduced new challenges for clinicians and patients, particularly in the realm of immune tolerance induction therapy. Carmen will delve into the impact of emicizumab on ITI therapy and provide practical insights into managing patients undergoing this treatment. So, sit back, relax, and join us in this insightful conversation with Carmen Escuriola-Ettingshausen. Do not forget to watch the full webinar on EAHAD Academy: https://academy.eahad.org/eahad/2023/module-2-iti-in-the-era-of-emicizumab/376716/carmen.escuriola-ettingshausen.module.2.iti.in.the.era.of.emicizumab.html?f=menu%3D25%2Ac_id%3D376716%2Afeatured%3D18172